Gwenn S Smith1, Georg Oeltzschner2, Neda F Gould3, Jeannie-Marie S Leoutsakos3, Najilla Nassery4, Jin Hui Joo3, Michael A Kraut2, Richard A E Edden2, Peter B Barker2, S Andrea Wijtenburg5, Laura M Rowland5, Clifford I Workman3. 1. Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: gsmith95@jhmi.edu. 2. Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, United States. 3. Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, United States. 4. Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. 5. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, United States.
Abstract
BACKGROUND: Magnetic resonance spectroscopy (MRS) methods have quantified changes in levels of neurotransmitters and neurometabolites in patients with major depression across the lifespan. The application of 7T field strengths and greater have not been a major focus of study in patients with late-life depression (LLD). METHODS: Nine LLD patients who met DSM-IV criteria for a current major depressive episode and nine non-depressed, healthy, age-matched controls underwent clinical and neuropsychological assessment and single-voxel 7T 1H-MRS at baseline and after 10-12 weeks of antidepressant treatment (Citalopram; patients only). Spectra were acquired from two brain regions implicated in both depressive symptoms and neuropsychological deficits in LLD, the anterior (ACC) and posterior cingulate (PCC). Levels of γ-aminobutyric acid (GABA), glutamate (Glu), glutathione (GSH), N-acetylaspartylglutamate (NAAG), N-acetylaspartate (NAA), and myo-inositol (mI) were quantified relative to total creatine (tCr) using linear-combination modeling. RESULTS: Baseline Glu/tCr levels were not significantly different between groups. Decreased Glu/tCr levels after Citalopram treatment were observed in a subset of LLD patients. Exploratory analyses showed that LLD patients had lower NAA levels in the PCC relative to controls. Higher levels of ml in the LLD patients relative to the controls and decreases after Citalopram treatment had large effect sizes but were not statistically significant. Further, decreases in PCC Glu/tCr and increases in ACC GSH/tCr were associated with improvement in depressive symptoms. LIMITATIONS: Sample size. CONCLUSIONS: These preliminary results suggest a role of neurochemicals and neurometabolites in the neurobiology of LLD and antidepressant treatment response.
BACKGROUND: Magnetic resonance spectroscopy (MRS) methods have quantified changes in levels of neurotransmitters and neurometabolites in patients with major depression across the lifespan. The application of 7T field strengths and greater have not been a major focus of study in patients with late-life depression (LLD). METHODS: Nine LLD patients who met DSM-IV criteria for a current major depressive episode and nine non-depressed, healthy, age-matched controls underwent clinical and neuropsychological assessment and single-voxel 7T 1H-MRS at baseline and after 10-12 weeks of antidepressant treatment (Citalopram; patients only). Spectra were acquired from two brain regions implicated in both depressive symptoms and neuropsychological deficits in LLD, the anterior (ACC) and posterior cingulate (PCC). Levels of γ-aminobutyric acid (GABA), glutamate (Glu), glutathione (GSH), N-acetylaspartylglutamate (NAAG), N-acetylaspartate (NAA), and myo-inositol (mI) were quantified relative to total creatine (tCr) using linear-combination modeling. RESULTS: Baseline Glu/tCr levels were not significantly different between groups. Decreased Glu/tCr levels after Citalopram treatment were observed in a subset of LLD patients. Exploratory analyses showed that LLD patients had lower NAA levels in the PCC relative to controls. Higher levels of ml in the LLD patients relative to the controls and decreases after Citalopram treatment had large effect sizes but were not statistically significant. Further, decreases in PCC Glu/tCr and increases in ACC GSH/tCr were associated with improvement in depressive symptoms. LIMITATIONS: Sample size. CONCLUSIONS: These preliminary results suggest a role of neurochemicals and neurometabolites in the neurobiology of LLD and antidepressant treatment response.
Authors: J J Luykx; K G Laban; M P van den Heuvel; M P M Boks; R C W Mandl; R S Kahn; S C Bakker Journal: Neurosci Biobehav Rev Date: 2011-06-06 Impact factor: 8.989
Authors: Kate E M Godfrey; Abby C Gardner; Sarah Kwon; William Chea; Suresh D Muthukumaraswamy Journal: J Psychiatr Res Date: 2018-08-11 Impact factor: 4.791
Authors: Gwenn S Smith; Charles F Reynolds; Patricia R Houck; Mary Amanda Dew; Yilong Ma; Benoit H Mulsant; Bruce G Pollock Journal: Am J Geriatr Psychiatry Date: 2002 Sep-Oct Impact factor: 4.105
Authors: Olga Voevodskaya; Konstantinos Poulakis; Pia Sundgren; Danielle van Westen; Sebastian Palmqvist; Lars-Olof Wahlund; Erik Stomrud; Oskar Hansson; Eric Westman Journal: Neurology Date: 2019-01-04 Impact factor: 9.910
Authors: Manoj K Doss; Michal Považan; Monica D Rosenberg; Nathan D Sepeda; Alan K Davis; Patrick H Finan; Gwenn S Smith; James J Pekar; Peter B Barker; Roland R Griffiths; Frederick S Barrett Journal: Transl Psychiatry Date: 2021-11-08 Impact factor: 6.222